PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Easyhaler (Budesonide) - Asthma

PAD Profile : Easyhaler (Budesonide) - Asthma

Keywords :
ICS, inhaled corticosteroids, respiratory, asthmatics

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Inhaler (dry powder)
Important Information :
Licensed in children.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024
Guidelines (Local)
01 November 2018

Committee Recommendations

Date
Committee Name
Narrative
04 November 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Budesonide Easyhaler may be considered in patients aged 12-17 if these other preferred, licensed devices are not suitable:

Clenil Modulite (beclometasone MDI) plus spacer (Volumatic, Able Spacer, Optichamber) or Qvar (beclometasone MDI) plus spacer (Aerochamber plus, Able Spacer, Optichamber) are the locally agreed preferred ICS devices.

If a breath activated device is necessary, consider:
Easyhaler Beclometasone (breath activated) DPI
Qvar Easi-Breathe (breath activated) MDI

Prescribe inhaler devices by BRAND to ensure consistency and avoid confusion

The guidelines for asthma can be found below

Associated BNF Codes

03. Respiratory System
03.02.00. Corticosteroids (respiratory)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More